KRAS mutation screening by chip-based DNA hybridization--a further step towards personalized oncology.

about

KRAS mutation screening by chip-based DNA hybridization--a further step towards personalized oncology.

Item

http://www.wikidata.org/entity/Q38906896

description

2015 nî lūn-bûn

@nan

2015年の論文

@ja

2015年学术文章

@wuu

2015年学术文章

@zh-cn

2015年学术文章

@zh-hans

2015年学术文章

@zh-my

2015年学术文章

@zh-sg

2015年學術文章

@yue

2015年學術文章

@zh

2015年學術文章

@zh-hant

name

KRAS mutation screening by chi ...... towards personalized oncology.

@en

type

Item

label

KRAS mutation screening by chi ...... towards personalized oncology.

@en

prefLabel

KRAS mutation screening by chi ...... towards personalized oncology.

@en

P1476

KRAS mutation screening by chi ...... towards personalized oncology.

@en

P2093

Carolin Steinbrücker

http://www.w3.org/2001/XMLSchema#string

Christine Steinbach

http://www.w3.org/2001/XMLSchema#string

Iver Petersen

http://www.w3.org/2001/XMLSchema#string

Joachim H Clement

http://www.w3.org/2001/XMLSchema#string

Jürgen Popp

http://www.w3.org/2001/XMLSchema#string

Karina Weber

http://www.w3.org/2001/XMLSchema#string

Katharina Walther

http://www.w3.org/2001/XMLSchema#string

Sibyll Pollok

http://www.w3.org/2001/XMLSchema#string

Yuan Chen

http://www.w3.org/2001/XMLSchema#string

P2860

Mutational Analysis of Circulating Tumor Cells Using a Novel Microfluidic Collection Device and qPCR Assay

COSMIC 2005

KRAS mutations as an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab.

K-ras mutations and benefit from cetuximab in advanced colorectal cancer.

Kirsten ras mutations in patients with colorectal cancer: the 'RASCAL II' study

High resolution melting analysis for the rapid and sensitive detection of mutations in clinical samples: KRAS codon 12 and 13 mutations in non-small cell lung cancer.

Comparison of Sanger sequencing, pyrosequencing, and melting curve analysis for the detection of KRAS mutations: diagnostic and clinical implications.

KRAS and BRAF mutation status in circulating colorectal tumor cells and their correlation with primary and metastatic tumor tissue.

Predicting response to EGFR inhibitors in metastatic colorectal cancer: current practice and future directions.

Influence of dangling ends and surface-proximal tails of targets on probe-target duplex formation in 16S rRNA gene-based diagnostic arrays.

P304

2747-2754

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1039/C4AN02086C

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

140

http://www.w3.org/2001/XMLSchema#string

P50

Dana Cialla-May

P577

2015-02-23T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

25706807

http://www.w3.org/2001/XMLSchema#string